Table 4. HLA-G 14 bp genotype in relation to sHLA-G levels in adult patient groups and healthy controls.
RA | HC | RA | HC | |||||
---|---|---|---|---|---|---|---|---|
HLA-G genotype | N (%) RA | N (%) HC | sHLA-G a (range b ) | sHLA-G a (range b ) | Pbonf c | LILRB1 recognition d (range e ) | LILRB1 recognition d (range e ) | Pbonf c |
del/del | 22 (32) | 11 (42) | 6.4 (1.5–131.9) | 5.5 (1.6–11.0) | 0.178 | 0 (0–155.9) | 17.3 (0–212.2) | 0.074 |
del/ins | 37 (55) | 11 (42) | 10.6 (0.5–104.6) | 5.9 (0.8–20.4) | 0.013 | 16.1 (0–117.1) | 14.7 (0–169.2) | 0.970 |
ins/ins | 9 (13) | 4 (15) | 5.5 (1.0–59.5) | 0.7 (0–2.1) | 0.020 | 50.8 (0–201.0) | 3.8 (0–24.6) | 0.148 |
P-value | 0.567 f | 0.534 g | 0.018 g | 0.200 g | 0.182 g |
amedian in ng/ml
b(minimum—maximum sHLA-G in ng/ml)
cComparison between patients and controls of the same genotype, Mann Whitney test
dmedian in units/ml (measured by LUMINEX)
e(minimum—maximum fluorescence intensity)
fComparison of genotype frequencies between patients and controls, Chi-square test
gComparison among genotypes, Kruskall-Wallis test
HC = healthy controls